The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

Completed · Phase 4 · Has a placebo group

Conditions studied: Chronic Gout, Hyperuricemia

In brief

Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.

Key facts

Study ID

NCT02956278

Run by

University of California, San Francisco

People needed

27

Starts

2016-11-01

Expected to finish

2018-03-01

Last updated by the study team

2020-06-23

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• self-identified as Asian/European ancestry
• generally healthy with approved lab values for CBC,HFP,RFP, and uric acid
• Subjects with the ABCG2 genotype, homozygous, heterozygous or homozygous for the major allele of rs2231142 will be recruited

You may not qualify if…

• vascular disease
• renal impairment
• medications/supplements that affect uric acid levels
• pregnant or lactating women
• prior history of allergic reaction to allopurinol or testing positive for HLA-B*5801 allele
• risk of urinary or gastric retention or narrow-angle glaucoma
• impaired hepatic function
• evidence of anemia
• evidence or diagnosis of congestive heart failure
• smokers
• subjects with a mutation other than rs2231142 in the ABCG2 genotype
• subjects taking hormonal contraceptives or other hormonal medications
• evidence of recreational drug use as determined by questionnaire

Where it is running

• Open Medicine Institute — Mountain View, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.